Advertisement

Hemiasterlin Analogues with Unnatural Amino Acids at the N-Terminal and Their Inhibitory Activity on Tumor Cells

  • Jiankun Qie
  • Wenxia Zhou
  • Xiunan Zhao
  • Junlin He
  • Yongxiang Zhang
  • Keliang LiuEmail author
Article

Abstract

Hemiasterlin is a tripeptide with highly alkylated unnatural amino acids. It acts as a potent tumor cell growth inhibitor. From the comparison of the N-terminal between hemiasterlin and its analogues, a further modification was conducted on this position for a SAR study. Some unnatural amino acids with aryl or ureido groups were introduced into the N-terminal of hemiasterlin analogues to improve their hydrophobicity/hydrophilicity. Here 14 hemiasterlin analogues were synthesized. And their activities against tumor cell lines were evaluated. Discussions on SAR preliminarily indicated that no matter whether the N-terminals come from the aryl or alkyl units, sufficient steric bulk, lipophilicity and methylation of the N-terminal should be crucial factors to the cytotoxic activity.

Keywords

Hemiasterlin analogues Tumor cell growth inhibitor Tripeptide Cytotoxic activity 

References

  1. Anderson HJ, Coleman JE, Andersen RJ, Roberge M (1997a) Cytotoxic peptides hemiasterlin, hemiasterlin A and hemiasterlin B induce mitotic arrest and abnormal spindle formation. Cancer Chemother Pharmacol 39:223–226PubMedCrossRefGoogle Scholar
  2. Andersen RJ, Coleman JE, Piers E, Wallace DJ (1997b) Total synthesis of (−)-hemiasterlin, a structurally novel tripeptide that exhibits potent cytotoxic activity. Tetrahedron Lett 38:317–320CrossRefGoogle Scholar
  3. Andersen R, Coleman J, Boberge M (1999a) Hemiasterlin analogs. WO 99/32509 July 1Google Scholar
  4. Anderson R, Piers E, Nieman J, Coleman J, Roberge M (1999b) Hemiasterlin analogs. CA2312826Google Scholar
  5. Coleman JE, Dilip de Silva E, Kong F, Andersen RJ, Allen TM (1995) Cytotoxic peptides from the marine sponge Cymbastela sp. Tetrahedron 51:10653–10662CrossRefGoogle Scholar
  6. Crews P, Farias JJ, Emrich R, Keifer PA (1994) Milnamide A, an unusual cytotoxic tripeptide from the marine sponge Auletta cf. constricta. J Org Chem 59:2932–2934CrossRefGoogle Scholar
  7. De Arruda M, Cocchiaro CA, Nelson CM, Grinnell CM, Janssen B, Haupt A, Barlozzari T (1995) LU103793 (NSC D-669356): a synthetic peptide that interacts with microtubules and inhibits mitosis. Cancer Res 55:3085–3092PubMedGoogle Scholar
  8. Fehrentz JA, Castro B (1983) An efficient synthesis of optically active α-(t-butoxylcarbonylamino)-aldehydes from α-amino acids. Synthesis 8:676–678CrossRefGoogle Scholar
  9. Gemble WR, Durso NA, Fuller RW, Westergaard CK, Johnson TR, Sackett DL, Hamel E, Cardellina JHII, Boyd MR (1999) Cytotoxic and tubulin-interactive Hemiasterlins from Auletta sp. and Siphonochalina spp. sponges. Bioorg Med Chem 7:1611–1615CrossRefGoogle Scholar
  10. He BL, Liu KL, Xiao SB (1989) Synthesis, resolution and protection of 4-cycloaminomethyl phenylalanines. Chin Sci Bull 34:997–1000Google Scholar
  11. Janssen B, Barlozzari T, Haupt A, Zierke T, Kling A (2000) Dolastatin 15 derivatives. US Patent 6,143,721,2000Google Scholar
  12. Julian PL, Karpel WJ, Magnani A, Meyer EW (1948) Synthesis of yobyrine, yobyrone and tetrahydroyobyrine. J Am Chem Soc 70:180–183PubMedCrossRefGoogle Scholar
  13. Kazmierski WM, Ferguson RD, Knapp RJ, Lui GK, Yamamura HI, Hruby VJ (1992) Reduced peptide bond cyclic somatostatin based opioid octapeptides, synthesis, conformational properties and pharmacological characterization. Int J Peptide Protein Res 39:401–414Google Scholar
  14. Kerbrat P, Dieras V, Pavlidis N, Ravaud A, Wanders J, Fumoleau P (2003) Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer. Eur J Cancer 39:317–320PubMedCrossRefGoogle Scholar
  15. Liu C, Masuno MN, MacMillan JB, Molinski TF (2004) Enanioselective total synthesis of (+)-milnamide A and evidence of its autoxidation to (+)-milnamide D. Angew Chem Int Ed Engl 43:5951–5954PubMedCrossRefGoogle Scholar
  16. Loganzo F, Discafani CM, Annable T, Beyer C, Musto S, Hari M, Tan X, Hardy C, Hernandez R, Baxter M, Singanallore T, Khafizova G, Poruchynsky MS, Fojo T, Nieman JA, Ayral-Kaloustian S, Zask A, Andersen RJ, Greenberger LM (2003) HTI-286, a synthetic analogue of tripeptide Hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res 63:1838–1845PubMedGoogle Scholar
  17. Loganzo F, Hari M, Annable T, Tan X, Morilla DB, Musto S, Zask A, Kaplan J, Minnick AA Jr, May MK, Ayral-Kaloustian S, Poruchynsky MS, Fojo T, Greenberger LM (2004) Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in α-tubulin. Mol Cancer Ther 3:1319–1327PubMedGoogle Scholar
  18. Mitra A, Sept D (2004) Localization of the antimitotic peptide and depsipeptide binding site on β-tubulin. Biochem 43:13955–13962CrossRefGoogle Scholar
  19. Nagase T, Mase T, Fukami T, Hayama T, Fujita K, Niiyama K, Takahashi H, Kumagai U, Urakawa Y, Nagasawa Y, Ihara M, Nishikibe M, Ishikawa K (1995) Linear peptide ETA antagonist: rational design and practical derivatization of N-terminal amino- and imino-carbonylated tripeptide derivatives. Bioorg Med Chem Lett 5:1395–1400CrossRefGoogle Scholar
  20. Nieman JA, Coleman JE, Wallace DJ, Piers E, Lim LY, Roberge M, Anderson RJ (2003) Synthesis and antimitotic/cytotoxic activity of hemiasterlin derivatives. J Nat Prod 66:183–199PubMedCrossRefGoogle Scholar
  21. Niu C, Smith D, Zask A, Loganzo F, Discafani C, Beyer C, Greenberger L, Ayral-Kaloustian S (2004) Tubulin inhibitors. Synthesis and biological activity of HTI-286 analogs with B-segment heterosubstituents. Bioorg Med Chem Lett 14:4329–4332PubMedCrossRefGoogle Scholar
  22. Nunes M, Kaplan J, Wooters J, Hari M, Minnick AA Jr, May MK, Shi C, Musto S, Beyer C, Krishnamurthy G, Qiu Y, Loganzo F, Ayral-Kaloustian S, Zask A, Greenberger LM (2005) Two photoaffinity analogues of the tripeptide, Hemiasterlin, exclusively label α-tubulin. Biochem 44:6844–6857CrossRefGoogle Scholar
  23. Porter J, Dykert J, Rivier J (1987) Synthesis, resolution and characterization of ring substituted phenylalanines and tryptophans. Int J Peptide Protein Res 30:13–21Google Scholar
  24. Poruchynsky MS, Kim JH, Nogales E, Annable T, Loganzo F, Greenberger LM, Sackett DL, Fojo T (2004) Tumor cells resistant to a microtubule-depolymerizing Hemiasterlin analogue, HTI-286, have mutations in α- or β-tubulin and increased microtubule stability. Biochem 43:13944–13954CrossRefGoogle Scholar
  25. Ravi M, Zask A, Rush TSIII (2005) Structure-based identification of the binding site for the Hemiasterlin analogue HTI-286 on tubulin. Biochem 44:15871–15879CrossRefGoogle Scholar
  26. Talpir R, Benayahu Y, Kashman Y, Pannell L, Schleyer M (1994) Hemiasterlin and Geodiamolide TA: two new cytotoxic peptides from the marine sponge Hemiasterella minor (Kirkpatrick). Tetrahedron Lett 35:4453–4456CrossRefGoogle Scholar
  27. Yamashita A, Norton EB, Kaplan JA, Niu C, Loganzo F, Hernandez R, Beyer CF, Annable T, Musto S, Discafani C, Zask A, Ayral-Kaloustian S (2004) Synthesis and activity of novel analogs of hemiasterlin as inhibitors of tubulin polymerization: modification of the A segment. Bioorg Med Chem Lett 14:5317–5322PubMedCrossRefGoogle Scholar
  28. Zask A, Birnberg G, Cheung K, Kaplan J, Niu C, Norton E, Yamashita Y, Beyer C, Krishnamurthy G, Greenberger L, Loganzo F, Ayral-Kaloustian S (2004a) D-piece modifications of the hemiasterlin analog HTI-286 produce potent tubulin inhibitors. Bioorg Med Chem Lett 14:4353–4358PubMedCrossRefGoogle Scholar
  29. Zask A, Birnberg G, Cheung K, Kaplan J, Niu C, Norton E, Suayan R, Yamashita A, Cole D, Tang Z, Krishnamurthy G, Williamson R, Khafizova G, Musto S, Hernandez R, Annable T, Yang X, Discafani C, Beyer C, Greenberger LM, Loganzo F, Ayral-Kaloustian S (2004b) Synthesis and biological activity of analogues of the antimicrotubule agent N,β,β-trimethyl-l-phenylalanyl-N 1-[(1S, 2E)-3-carboxy-1-isopropylbut-2-enyl]-N 1, 3-dimethyl-l-valnamide (HTI-286). J Med Chem 47:4774–4786PubMedCrossRefGoogle Scholar
  30. Zask A, Kaplan J, Musto S, Loganzo F (2005) Hybrids of the Hemiasterlin analogue Taltobulin and the Dolastatins are potent antimicrotubule agents. J Am Chem Soc 127:17667–17671PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Jiankun Qie
    • 1
  • Wenxia Zhou
    • 1
  • Xiunan Zhao
    • 1
  • Junlin He
    • 1
  • Yongxiang Zhang
    • 1
  • Keliang Liu
    • 1
    Email author
  1. 1.Beijing Institute of Pharmacology and ToxicologyBeijingPeople’s Republic of China

Personalised recommendations